Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Effect of Obinutuzumab Versus Rituximab in PR3-Patients With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Conditions
Interventions
Obinutuzumab
Rituximab
Locations
3
United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Mayo Clinic Rochester
Rochester, Minnesota, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Start Date
June 30, 2023
Primary Completion Date
May 7, 2024
Completion Date
May 7, 2024
Last Updated
July 31, 2024
NCT07168161
NCT06983821
NCT03004326
NCT07339540
NCT05979051
NCT06828042
Lead Sponsor
Mayo Clinic
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions